The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The GCC idiopathic pulmonary fibrosis treatment market is expected to exhibit a CAGR of 11.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Idiopathic pulmonary fibrosis (IPF) refers to a chronic lung disease that affects the tissue surrounding the air sacs. This condition causes the buildup of scar tissues in the alveoli, which hinders its oxygen-carrying functionalities. The common symptoms of IPF include breathing difficulties, dry cough, fatigue, loss of appetite, and swollen limbs. IPF is diagnosed via various chest imaging evaluations, like antibody tests, lung biopsies, and pulmonary function tests. Its treatment plan includes anti-fibrotic drugs and other supportive treatment options, such as oxygen therapy and palliative care.
The rising prevalence of fibrotic diseases, especially among the geriatric population, represents the key factor driving the GCC IPF treatment market growth. Improving living standards and the increasing consumption of nicotine-based products are further catalyzing the market growth. Moreover, rapid advancements in the IPF diagnostic techniques are propelling the market growth. In line with this, leading players are undertaking several initiatives to create awareness regarding the disease. For instance, in 2020, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched a website customized in the Arabic language to conveniently cater to the increasing demand for effective management strategies of IPF. Such measures are positively influencing the GCC market growth for IPF treatment.
IMARC Group provides an analysis of the key trends in each sub-segment of the GCC idiopathic pulmonary fibrosis treatment market, along with forecasts at the country and regional level from 2022-2027. Our report has categorized the market based on drug class and end user.
Breakup by Drug Class:
Breakup by End User:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug Class, End User, Country|
|Region Covered||Saudi Arabia, UAE, Qatar, Oman, Kuwait, Bahrain|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at